HK2 and cancer: AKT inhibitor LY294002 could suppress the expression of p-AKT, c-Myc, HK2, PKM2, and pro-caspase3 and inhibited the viability in HepG2 cells, suggesting the important role of AKT suppression in regulation of cancer metabolism (Shin et al., 2021).